tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Jason Zemansky, 52 are a BUY (59.77%), 33 are a HOLD (37.93%), 2 are a SELL (2.3%).
Analyst Jason Zemansky, currently employed at BAML, carries an average stock price target met ratio of 45.18% that have a potential upside of 9.1% achieved within 80 days.
Jason Zemansky’s has documented 170 price targets and ratings displayed on 19 stocks. The coverage is on Healthcare, Financial Services sectors.
Most recent stock forecast was given on BIIB, Biogen at 21-Jul-2026.
Analyst best performing recommendations are on INSM (INSMED).
The best stock recommendation documented was for INSM (INSMED) at 5/24/2024. The price target of $40 was fulfilled within 4 days with a profit of $18 (81.82%) receiving and performance score of 204.55.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$3
$1.79 (147.93%)
$3
2 years 17 days ago
(26-Sep-2024)
0/4 (0%)
$2.42 (417.24%)
Hold
$7
2 years 3 months 23 days ago
(20-Jun-2024)
1/3 (33.33%)
$0.45 (6.87%)
57
Sell
$1
$-0.21 (-17.36%)
$1.5
2 years 8 months 26 days ago
(17-Jan-2024)
6/6 (100%)
$-0.02 (-1.96%)
278
Buy
2 years 9 months 25 days ago
(18-Dec-2023)
1/1 (100%)
$32.69 (83.16%)
358
Buy
$9
$7.79 (643.80%)
3 years 5 months 2 days ago
(11-May-2023)
2/4 (50%)
$4.84 (116.35%)
178
Which stock is Jason Zemansky most bullish on?
Which stock is Jason Zemansky most reserved on?
What Year was the first public recommendation made by Jason Zemansky?
